Jazz Pharmaceuticals Plc Share Price (JAZZ.US)

248.47..4.30 (1.76%) ...Bid: 247.00....Ask: 250.00...Spread: 3.00 (1.215%)

Market Cap: $15.29b

Sold a small amount in ISA . $249 ( 1.5% charge no extra fee so keep dealing small amounts )

237.84...7.82 (3.40%) ...Bid: 237.34...Ask: 237.87....Spread: 0.53 (0.22%)

Market Cap: $14.45b

Sold top up on 16th June back for $236 target for that one .

Moving back towards the all time high again after that little pull back hopefully .

226.73...-3.86 (-1.67%) ..Bid: 226.73....Ask: 227.03...Spread: 0.30 (0.132% )

Bought back for $226 above the 220 target .

The sale at $240 "took another slice 4th June under target ( Addicted and looking for deals ) "

239.01...8.08 (3.50%) ...Bid: 238.90...Ask: 239.28...Spread: 0.38 (0.159%)

Market Cap: $14.19b

Took another slice under target ( Addicted and looking for deals )

Jazz Pharmaceuticals advanced over the past month, buoyed by a significant first-quarter earnings beat and positive pipeline updates. Analysts project continued momentum in the third quarter of 2026, driven by the anticipated FDA approval of zanidatamab and double-digit growth in its oncology and epilepsy portfolios.

..............................................................................................................................

$235.75..+6.20...(+2.70%)

https://www.google.com/finance/beta/quote/JAZZ:NASDAQ

Sliced again for *$235.2 all time high .

Still have large holding , plus in ISA which will not allow rebuy .

3rd Sell in a row now.

Average Price Target: ~$242.00 – $250.00

6th this year 2026 ( two buy backs )

UBS Upgrade: On May 19, 2026, UBS upgraded JAZZ to Buy from Neutral, significantly raising its price target to $307.

This shift reflects confidence in Ziihera, a gallbladder cancer treatment with an FDA regulatory deadline of August 25, 2026.